31 results about "Liver necrosis" patented technology

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

The present application relates to the technical field of medicine, and discloses application of gastrodin in preparation of medicine for preventing and treating radioactive liver injury, wherein the radioactive liver injury is liver injury caused by ionizing radiation exposure. It is found that the gastrodin can effectively intervene in specific mechanism of the radioactive liver injury, significantly reduce the mortality of the radioactive liver injury mice, reverse the hepatic veno-occlusive disease and the core pathological features of liver fibrosis of the radioactive liver injury, and more specifically treat the radioactive liver injury. On the other hand, the gastrodin can be used before radiation exposure to prevent serious radioactive liver injury after radiation exposure.

The invention discloses an application of harpagoside in preparation of a medicine for preventing and / or treating hepatic fibrosis. The invention discloses an application of harpagoside in preparation of a health care product with an auxiliary protection effect on chemical liver injury. The animal level proves that the harpagoside can reduce hepatic fibrosis such as chemical hepatic fibrosis induced by carbon tetrachloride, reduce liver collagen deposition, reduce hydroxyproline content in hepatic tissue, reduce increased HA and Col IV content in serum, and reduce expression of fibrosis and collagen deposition related genes, so that the harpagoside can be used for treating hepatic fibrosis. The traditional Chinese medicine composition has a good effect of treating or preventing hepatic fibrosis.

The invention discloses an application of 5-methoxyl serotonin in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and systematically proves that the 5-methoxyl serotonin (5MOS) has the effects of relieving hepatic fibrosis, improving accumulation of bile acid in the liver and reversing metabolism and transport of the bile acid for the first time, so that the cholestatic liver diseases can be prevented and / or treated by the 5-methoxyl serotonin (5MOS). DDC-induced cholestatic liver injury is relieved in a dose-dependent manner, and a new medication strategy is provided for treating cholestatic liver diseases.

The application belongs to the technical field of biomedicine, and discloses a method for constructing a Channa argus bile stasis model. The application discloses application of rifampicin or a pharmaceutically acceptable salt thereof in construction of a fish liver injury model. The application discloses, for the first time, that the antibiotic rifampicin widely used in aquaculture is used to construct a fish liver injury model. The model is closer to the real scene of the use of a large amount of drugs when bacterial diseases break out in production practice. The injury type of the fish liver injury model is clearly directed to bile stasis, which fills the research blank of the disease model of the fish, and is different from common hepatocyte necrosis or fatty liver models.

The present application relates to a kind of VSIG4 based on reversible immunological affinity magnetic bead separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation The isolated cells of the present application can reduce liver inflammation and injury, and effectively treat acute liver injury and acute liver failure. The isolation method of the present application is fast, mild and efficient, and the obtained cells are functional and suitable for adoptive cell therapy, which has a broad clinical application prospect.

The invention relates to the field of biological medicines, and discloses application of an OGG1 micromolecule agonist in preparation of a medicine for treating liver inflammatory diseases. According to the micromolecule TH10785, by activating the beta, delta-lyase activity of DNA repair enzyme OGG1, the oxidized DNA repair capacity is remarkably enhanced, ROS accumulation in liver cells is reduced, NF-kappa B signal channel activation and proinflammatory factor release are inhibited, and therefore liver inflammation and fibrosis are effectively relieved. Meanwhile, the medicine can inhibit the activation of B cells and the formation of plasma cells, finally reduces the generation of autoimmune antibodies, and improves the immune imbalance state of autoimmune hepatitis. The invention provides an innovative treatment strategy based on OGG1 enzyme function amplification, and a new pharmacological approach is provided for treatment of chronic liver diseases and immunological liver injury.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

The invention discloses application of solamargine in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. By simulating a classical Mdr2- / -mouse model of clinical cholestasis pathology, the solamargine is researched and proved to treat cholestatic liver injury by improving hepatocyte injury, bile duct dysfunction and bile metabolism disorder, and the solamargine shows good application potential in clinical treatment of cholestatic liver diseases.

The present application belongs to the technical field of medicine, and relates to a kind of pharmaceutical composition and its application in preparation for treating or preventing liver fibrosis drug. A kind of pharmaceutical composition for treating or preventing liver fibrosis, the pharmaceutical composition includes as active ingredient the protocatechuic acid (PCA) and gimalin (GER). The present application first confirms that protocatechuic acid and gimalin combined application has significant synergistic effect in the treatment of liver fibrosis, and its curative effect is better than any single compound single administration, can more effectively reduce liver injury index, improve liver pathological morphology, reduce intrahepatic collagen deposition. Based on its clear mechanism of action, the composition of the present application is especially suitable for treating liver fibrosis related to abnormal expression of RIPK3.

The present application relates to the technical field of biotechnology, and particularly relates to a lysosome-targeted calcium ion fluorescent probe and application thereof. The calcium ion fluorescent probe provided by the present application has high sensitivity fluorescent response to calcium ions, and is not interfered by pH, and can be used for monitoring dynamic changes of lysosome calcium ions. Meanwhile, the lysosome calcium ion fluorescent probe in the present application has good biocompatibility, low background fluorescent interference and other advantages, makes up for the deficiency of traditional commercialized calcium ion fluorescent probes, and has wide application prospect in the field of acute liver injury and other liver diseases in vivo.

This invention relates to the field of biomedicine, specifically to the application of dimethylhydroquinone in improving ischemia-reperfusion-related injury of the heart and liver. 2,6-DMHQ can reduce serum ALT and AST, improve liver necrosis, and also reduce serum myocardial enzyme levels CK, CK / MB, and LDH, thereby reducing the area of ​​myocardial infarction.

The invention relates to the technical field of medicines, and discloses application of gastrodin in preparation of a medicine for preventing and treating radioactive liver injury, and the radioactive liver injury is liver injury caused by ionizing radiation exposure. The gastrodin is found to be capable of effectively intervening a specific mechanism of the radiation-induced liver injury, so that the death rate of mice with the radiation-induced liver injury is remarkably reduced, meanwhile, the core pathological characteristics of hepatic vein occlusion and hepatic fibrosis of the radiation-induced liver injury are reversed, and the radiation-induced liver injury is treated in a more targeted manner. On the other hand, gastrodin is used before radiation exposure, so that serious radioactive liver injury after radiation exposure can be prevented.

According to a sepsis mouse model, it is found that phytolaccin can reduce the liver necrosis area and the inflammatory focus caused by sepsis by reducing the content of alanine aminotransferase, glutamic oxalacetic transaminase, serum creatinine and lactic dehydrogenase, so that the application of phytolaccin to preparation of the medicine for treating sepsis is achieved, and the application of phytolaccin to preparation of the medicine for treating sepsis is achieved. The lung inflammation, alveolar wall thickening and inflammatory cell infiltration are improved, so that the organ injury caused by sepsis is relieved. Meanwhile, the phytolaccin can also regulate the polarization state of macrophages to a balanced state in an inflammatory storm state, so that the release of proinflammatory factors is inhibited, and the effect of preventing and treating sepsis is achieved.

The present disclosure relates to a new water-soluble fullerene derivative and a preparation method thereof, and application of the water-soluble fullerene material in preventing and treating liver damage / liver failure. The fullerene material of the present disclosure can efficiently scavenge active free radicals, reduce liver oxidative stress, restore normal liver function indicators, reduce liver necrosis, and prevent and treat drug-induced liver damage / liver failure.

The invention discloses an application of CA170 in preparation of a medicine for treating echinococcus multilocularis, and aims to realize effective treatment on echinococcus multilocularis infection. C57 / 6J mice infected by hepatic portal veins for 40 days through alveolar coccosis serve as research objects, CA-170 micromolecules are orally administrated, the dosage of CA-170 in the medicine is not lower than 10 mg / kg, the CA-170 is treated once every three days for one month, and the drug effect of CA-170 on protoscolex cystic development and focus growth in the bodies of the echinococcus multilocularis infected mice is detected. Results show that compared with a solvent control group, in-vivo focuses of mice in a CA-170 treatment group are reduced, and the number and the weight of echinococcosis cysts are remarkably reduced, indicating that CA170 shows a good effect in the aspect of resisting echinococcosis multilocularis infection, and can reduce the proportion of MDSC caused by the infection and relieve liver injury caused by the infection. According to the application scheme provided by the invention, technical support is provided for efficiently preventing and treating the echinococcosis multilocularis, and a foundation is laid for clinical treatment of the CA-170 on the echinococcosis multilocularis.

The invention discloses a liver small molecule peptide as well as a preparation method and application thereof, and belongs to the technical field of functional peptides. The small molecule peptide prepared by the preparation method provided by the invention effectively retains active factors in animal livers, can stimulate rapid proliferation of hepatocytes, and can reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in serum of mice with liver injury in a short time; necessary raw materials can be continuously provided for liver cell regeneration, and the liver-protecting composition has a good application prospect in protecting liver health and maintaining / recovering damaged liver functions; the beverage is fragrant, sweet, fine and smooth in taste, free of unpleasant odor, free of preservatives, free of toxic and harmful substances, high in safety and wide in applicable crowd.

The invention provides a recombinant adeno-associated virus vector, a product and application of the recombinant adeno-associated virus vector to treatment of hemophilia A, and belongs to the technical field of biological medicine. A recombinant AAV vector is prepared on the basis of an hFVIII nucleotide sequence with B structural domain deletion as shown in SEQ ID NO.1 or SEQ ID NO.2 or an optimized nucleotide variant sequence, the recombinant AAV vector has the characteristic of targeting liver, a human VIII factor gene can be delivered to liver cells of a patient diagnosed as type A hemophilia by using a replication-deficient adeno-associated virus, and the human VIII factor gene is promoted to be efficiently expressed, so that the recombinant AAV vector can be used for treating the type A hemophilia. The use dosage is not higher than 2 * 10 < 13 > vg / kg, and the risk of liver injury caused by high dosage is avoided from the source. The hemorrhage symptom of hemophilia patients can be relieved, a brand new technical normal form is provided for the A-type hemophilia from symptomatic blood transfusion to safer and more effective gene therapy, and the development of precise treatment of hereditary blood coagulation disorder diseases is promoted.

The invention provides an application of selenium-rich probiotics in preparation of a preparation for treating fluoxetine-induced liver injury, and relates to the technical field of biological medicine, the application is characterized in that Se-BL is obtained by reducing sodium selenite through ascorbic acid and modifying the surface of bifidobacterium longum, and nano-scale selenium dots are formed. The preparation plays a role through dual mechanisms: active oxygen (ROS) is directly removed, an Nrf2 pathway is activated, and the liver oxidation resistance (GSH, SOD) is improved; the traditional Chinese medicine composition is capable of inhibiting NF-kappa B inflammation signal channels, reducing proinflammatory factors (TNF-alpha and IL-6) and synchronously regulating intestinal flora so as to enhance the intestinal barrier function. Experiments prove that the traditional Chinese medicine composition can remarkably reduce the level of serum transaminase (ALT / AST / ALP) and relieve liver tissue necrosis and lipid peroxidation damage (MDA), the dosage form of the traditional Chinese medicine composition is an oral preparation, and each dose of the traditional Chinese medicine composition contains 1 * 10 <-1 > * 10 <-1 > CFU of Se-BL viable bacteria. The selenium-modified probiotics are used for antagonizing hepatotoxicity of mental drugs for the first time, and an innovative therapy is provided for fluoxetine-induced drug-induced liver injury (DILI) and acute hepatic failure (ALF).

This invention relates to the field of genetic engineering technology, and in particular to the application of a deacetylated NDP52 protein in the preparation of drugs for controlling Salmonella infection. This application provides a deacetylated NDP52 protein, a gene encoding the deacetylated NDP52 protein and its nucleotide sequence, and includes a recombinant vector containing the gene, a transgenic cell line or recombinant virus, and a substance capable of deacetylation of the NDP52 protein. The application of the gene, the protein, and the substance for deacetylation of the NDP52 protein in the preparation of drugs for controlling Salmonella infection demonstrates that expressing NDP52 and its deacetylated variants in mouse liver effectively promotes the clearance of bacterial infection in the liver and reduces liver necrosis, providing a scientific basis and potential tool for the treatment of bacterial infectious diseases.

The invention belongs to the field of medicines, and discloses application of nicotiflorin in preparation of medicines for treating metabolism-related fatty liver diseases / metabolism-related steatohepatitis diseases. The invention discloses application of nicotiflorin in preparation of a medicine for treating fatty liver diseases related to metabolic dysfunction and application of nicotiflorin in preparation of a medicine for treating hepatic fibrosis or slowing down the development process of hepatic fibrosis. The invention discloses an application of nicotiflorin in preparation of a health care product with an auxiliary protection effect on chemical liver injury. The nicotiflorin can obviously reduce the lipid content of AML-12 cells induced by palmitic acid and obviously reduce the expression of alpha-SMA and Collagen1 of human hepatic stellate cells, so that the activation of LX-2 cells is inhibited, and the liver fibrosis induced by CCl4 is obviously improved.

The application discloses a preparation method of lentinan extract, a product and application thereof, and discloses that the beta-glucan content of eight lentinus edodes varieties is quite different, and the beta-glucan content of the fruiting body of Hu Xiang F2 is the highest. The lentinan extract prepared by the application has the activity of repairing liver injury, and can inhibit the proliferation of tumor cells by activating macrophages and enhancing the phagocytosis of the macrophages.

The application belongs to the technical field of biological medicine, and particularly relates to POFUT1 The application discloses an application of a gene function inhibitor in preparation of a drug for treating cholestatic liver disease. POFUT1 It is found for the first time that inhibition of the function of the gene can significantly reduce the degree of liver lesion of cholestatic liver disease. POFUT1 The deletion of the gene can significantly reduce serum liver enzyme, bile acid and bilirubin levels, reduce liver inflammatory cell infiltration and collagen deposition. Further verification by AAV8-mediated RNA interference technology shows that targeted silencing of the gene in liver cells can effectively alleviate liver injury and liver fibrosis. POFUT1 The application provides a novel treatment target and strategy for cholestatic liver disease, and has a wide clinical application prospect.

The use of 2,6-DMHQ in ischemia-reperfusion-related injuries, preferably against cardiac and hepatic ischemia-reperfusion injuries. 2,6-DMHQ can reduce serum ALT and AST and ameliorate liver necrosis. 2,6-DMHQ can also reduce the cardiac enzyme profile, including CK, CK / MB and LDH, and reduce myocardial infarct size.

The invention discloses an application of anagloside C in preparation of a medicine for preventing and / or treating hepatic fibrosis. The invention discloses an application of anagloside C in preparation of a health care product with an auxiliary protection effect on chemical liver injury. The animal level proves that the anagloside C can reduce hepatic fibrosis such as chemical hepatic fibrosis induced by carbon tetrachloride, reduce liver collagen deposition, reduce hydroxyproline content in hepatic tissue, reduce increased HA and Col IV content in serum and reduce expression of fibrosis related genes and proteins, so that the anagloside C can be used for treating hepatic fibrosis. The traditional Chinese medicine composition has a good effect of treating or preventing hepatic fibrosis.

The invention relates to the technical field of liver inflammation. The invention provides an application of phosphatidyl ethanolamine in induction of NK cell ferroptosis. The invention discloses the new application of the metabolite PE for relieving immunological liver injury by inducing NK cell ferroptosis for the first time, and provides a clear target spot and direction for developing a brand new medicine for treating the diseases. The action mechanism of the invention focuses on regulation of ferroptosis of NK cells, which is a relatively specific immune regulation mode, and compared with the traditional broad-spectrum immunosuppressor, the application has the potential of smaller side effect and higher accuracy. Experiments prove that PE can effectively induce ferroptosis of NK cells to cause mitochondrial function damage of the NK cells and significantly inhibit the ability of the NK cells to secrete inflammatory cytokines, and the reliability of the therapeutic effect of the PE is verified from the functional level.

The present invention addresses the problem of providing a method for forming a complex tissue structure and preparing a liver organoid that faithfully reproduces a healthy liver in which a pathological state can be mimicked by a simple process, and further providing a simple method for preparing a steatotic liver disease model organoid in which it is possible to reproduce the degeneration and complex hepatopathy that are specific to steatotic liver disease.　Provided is a method for producing a multilayered liver organoid, said method including: a cocultivation step for cocultivating source cells; a differentiation inducement step for inducing differentiation of the source cells; and a tissue construction step for constructing a tissue structure that is composed of a plurality of layers of cells, wherein the source cells include hepatoblasts, vascular endothelial progenitor cells, and mesenchymal cells.

The invention discloses an application of Sovleplenib in preparation of a product for treating autoimmune liver diseases, and belongs to the field of medicines. According to the application disclosed by the invention, the influence of the Sovleplenib on the autoimmune liver disease is systematically studied from the aspects of serology, pathological histology and the like, and the result shows that the Sovleplenib can effectively relieve related indexes of mouse liver injury, recover the liver function of the mouse, relieve the phenomena of liver necrosis, inflammation aggregation, cholestasis, bile duct hyperplasia and the like of the mouse and delay the progress of the autoimmune liver disease. Therefore, the invention provides a theoretical research basis for development of Sovleplenib for treating autoimmune liver diseases.